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Cancer is a large group of diseases which arises from one single cell, grows 
uncontrolled and may spread to other organs 
1
. According to WHO Cancer Report 
(2015), it is one of the leading causes of morbidity and mortality in the modern world 
with 8.2 million deaths in 2012 and 22 million expected cases within the next 2 decades 
2
. Latest statistics show that colon cancer is globally the third most commonly 
diagnosed cancer type and specifically the only cancer observed with approximately 
equal frequency in men and women 
3
. Cancer is globally an important area of 
therapeutic interest. The high number of deaths is a crucial reason for science to develop 
new approaches and novel compounds for its treatment. 
The non-selectivity and acute toxicity of many antitumor agents has prompted 
the search for new antitumor agents with improved tumor selectivity, efficiency and 
safety. Herein, our latest results on the synthesis of a novel chemical family of 
spirooxindoles containing an 1,3,4-oxadiazoline five-membered ring will be presented. 
These two scaffolds (spirooxindole and oxadiazole) are separately reported to have in 
vitro antitumor activity as p53/MDM2 inhibitor 
4,5
. However, oxindole joined with 
1,3,4-oxadiazoline ring in the same molecule was never studied before as anti-tumor 
agents. The synthesis was performed by 1,3-dipolar cycloaddition between derivatives 
of indoline-2,3-diones and hydrazonyl chlorides. Using this method, twelve compounds 
were obtained with high yields. Additionally, all compounds were tested in vitro in 
three different colorectal cancer cell lines: an isogenic matched pair of wild type p53 




], and a 
human colorectal adenocarcinoma cell line [SW620 (mut p53)], in order to report cell 
growth inhibitory activity. From the library of spirooxadiazoline oxindoles, quite 
remarkably, IC50 values of four compounds were calculated. Three compounds 
displayed IC50 values below 10 µM and antiproliferative activity in SW620 cell line. 
Importantly, one compound significantly decreased SW620 cell viability, while it did 
not decrease normal fibroblasts viability. This indicates that compound 32a associated 
cytotoxicity is specific for tumor cells. In sum, spirooxadiazole oxindoles may represent 
a promising scaffold for the development of new antitumor agents. Ongoing studies are 
directed to ascertain their molecular mechanism of action and cellular toxicity, in order 
to confirm their potential as antitumor agents. 
xx 
 
Keywords: Spirooxindoles; spirooxadiazoline; 1,3-dipolar cycloaddition; colorectal 




























O cancro é um grande grupo de doenças que surge a partir de uma única célula, 
cresce descontrolado e pode se espalhar para outros órgãos 
1
. De acordo com o 
Relatório da OMS (2015), o cancro é uma das principais causas de morbidade e 
mortalidade no mundo moderno, com 8.2 milhões de mortes em 2012 e 22 milhões de 
casos esperados nas próximas 2 décadas 
2
. As últimas estatísticas mostram que o cancro 
do cólon é o terceiro tipo de cancro mais diagnosticado eo único cancro observado com 
aproximadamente igual frequência em homens e mulheres 
3
. O elevado número de 
mortes por cancro torna prioritária, na área de investigação na saúde, a descoberta de 
novas famílias de compostos com atividade anticancerígena. 
A falta de selectividade, assim como a toxicidade aguda de muitos agentes 
anticancerígenos, levou à necessidade de desenvolver novos agentes antitumorais com 
uma melhor selectividade tumoral, eficiência e segurança. Nesta dissertação, são 
apresentados resultados obtidos no desenho e síntese de uma nova família de 
espirooxindoles contendo um anel de cinco membros de oxadiazolino como potenciais 
agentes antitumorais. Os compostos finais resultam da junção de duas estruturas 
químicas (espirooxindole e oxadiazole) na mesma moléculas, que isoladamente estão 
descritas como tendo actividade antitumoral 
4,5
. A síntese foi realizada por cicloadição 
1,3-dipolar entre derivados de indole-2,3-dionas e dipolos-1,3 (gerados in situ a partir 
de cloretos de hidrazonilo). Doze compostos finais foram obtidos com rendimentos 
elevados, os quais foram testados in vitro em três linhas celulares de cancro colo-rectal: 





], e uma linha celular de adenocarcinoma colo-
rectal humano [SW620 (mut p53)]. Três compostos apresentaram valores de IC50 abaixo 
de 10 µM na linha celular SW620. Em particular, foi obtido um composto promissor 
para o desenvolvimento de novos agentes anticancerígenos, que diminuiu 
significativamente a viabilidade das células SW620, não tendo apresentado 
citotoxicidade em fibroblastos de colon humano normal, para as concentrações testadas.  
Palavras-chave: Spirooxindoles; spirooxadiazoline; cicloadição 1,3-dipolar; cancro 
















































Cancer is defined by World Health Organization (WHO) as a large group of 
diseases (malignant tumors) which affects any part of the body as a result of personal 
genetic factors and external agents such as; physical, chemical and biological 
carcinogens 
6
. When the normal cells mutate into tumor (abnormal) cells, they split 
rapidly and grow uncontrollably in a multistage process. They can even spread to other 
organs through the lymphatic system or bloodstream which is called a metastasis 
7
.  
WHO reported, from 184 countries worldwide, that approximately 14 million 
new cases and 8.2 million deaths happened in 2012 because of cancer 
8
. Moreover, in 
economically developing countries, cancer was reported with increasing numbers due to 
changes in lifestyle 
9
. According to GLOBOCAN 2012 results, 64% of the cancer 
deaths occurred in economically developed countries 
10,8
. The main risk factors are 
smoking, consumption of saturated fat, highly refined foods, sedentary lifestyles and 
daily stress as a result of the urbanization and modernization 
11
. Until now, several 
achievements against cancer were gained and the mortality was reduced with the 
improvements of early detection, screening and treatment in specific cancers. 
Nonetheless, cancer is still one of the major threat to the world health 
 12,13
. 
Cancer is the result of lack of apoptosis which causes malignant cells to keep 
growing without dying 
14
. Apoptosis and cell cycle arrest are processes in organisms in 
which DNA is under threat of damage. The period of cell cycle arrest has the 
opportunity to repair the damaged DNA, however, apoptosis results in direct cell death 
15
. 
A transcription factor, p53, is the regulatory key tumor suppressor protein that 
chooses to carry apoptosis in the cells with damaged DNA 
15
. It was discovered over 35 
years ago and is generally considered as “guardian of the genome”. It has several roles 
on the regulation of biological processes such as DNA repair, cell survival, cell death, 
proliferation, growth, senescence, differentiation, motility and metabolism 
16
. It is 
known that uncontrolled cell proliferation is the most important step for tumor cells 




indirect ways. This can be caused by oxidative stress, DNA damage, nutrient 
deprivation, replicative stress, etc. In these cases, p53 modifications induce p53 
activation in the cell. If the level of stress is low, p53 promotes cell cycle arrest to repair 
its genome. On the other hand, if damage is on too serious levels, p53 starts apoptosis or 






Figure 1.1 - The view of p53 activating signals and responses (adapted from18). 
 
 
Once the cancer cells find out the inhibition of p53 controlled pathways, they 
suppress the regulation of apoptosis and sustain the cell cycle progression 
14
. The 
mutations in p53 protein and the decreased expression of caspases breaks the balance 
between cell division and cell death 
19
. Studies indicate that among all human tumors, 
approximately half have a mutated p53 gene 
15
. Therefore, there is no surprise that p53 






According to the statistics, globally around 22 million cancer patients were 
identified who had defects in p53 signaling. Considering that almost 50% of them keep 
the mutant p53, without tumor suppressor function, the rest will retain a wild-type p53 
21
. Recently, Joerger et al. repaired the function of p53 tumor suppressor in mutant p53 
cancer cell lines with chemical chaperons analyzing the structural and functional effects 
of p53 cancer mutations 
22
. 
Colorectal cancer is the fourth leading cause of death but also the third most 
commonly diagnosed cancer in the world based on the recent statistics 
23
. According to 
this statistics, the number of incidence for men is higher than for women and the rates 




Figure 1.2 - Global colon cancer statistics (adapted from 24). 
 
Moreover, the latest statistics of cancer incidence by GLOBOCAN (2012) show 
that in the European Union colorectal cancer is the second most common cancer and 
death cause with number of victims 447.000 and 215.000 respectively. Among the 
countries in Europe, Slovakia, Hungary, Denmark and Croatia have the highest 
incidence and mortality numbers from colorectal cancer for both sexes 
24
.  
According to the statistics, estimated numbers for colon cancer in 2030 will 






Moreover, incidence rates show that nearly every 1 in 20 Americans have a possibility 
to be diagnosed with colon cancer in their lifetime. Nevertheless, researches proved that 
colon cancer develops slowly between the period of time from 10 to 20 years. As any 
other cancer types, colon cancer also reveals resistance against drugs and therapies 
26
. 
With the objective of finding novel molecules to target this tumor, in this thesis, all 
biologic experiments were carried out using colon cancer cells. 
 
1.2 Oxindole scaffold 
The bicyclic oxindole scaffold with one carbonyl (-C=O) group and one amino 
(NH) group has high importance in medicinal chemistry. Among several combinations, 





 positions. Additionally, the anti-cancer potential is higher, if substituents 
on these positions are bulky structures 
27
. 
                    
Figure 1.3 - Isatin and oxindole structures. 
 
 
Isatin was discovered in 1841, by Erdman and Laurent, and named as 1H-indole-
2,3-dione. Product was obtained from the oxidation of indigo by nitric and chromic 
acids (Fig 1.3). Isatin can be found in a large variety of heterocyclic compounds, such 
as indolines and quinolones, or can be used as precursor for drug synthesis being 
synthetically versatile substrates 
28
. During the last decades, isatin derivatives have been 
reported with high biological activities as being a part of tuberculostatic and antitumor 
agents and substances with anti-HIV, antimicrobial, anti-inflammatory, antiviral and 
antifungal effects. Additionally, they can be useful in the synthesis of dyes and 
analytical reagents. There are more studies regarding the mechanism of action of isatin 
derivatives, which are the inhibition/modulation of proteases, translation initiation, neo-








Studies indicated that oxindoles could be obtained from synthetic or natural origin 
with fascinating biological activities. Until now, several oxindole derivatives were 
tested against different diseases such as cancer, inflammation and bacterial infection. 
Some of these derivatives exhibited high potential and reached clinical trials. Among 




Figure 1.4 – Isatin based structures 1-3 which are already in the market. 
 
Chronologically, Methisazone (1) has been used as anti-viral drug since 1965. 
After US-FDA approved the novel structure, Sunitinib (2) in 2006, which is kinase 
inhibitor for the treatment of gastrointestinal stromal tumors and advanced renal 
carcinoma. It is on the market as Sutent® by Pfizer. The mechanism of action is to 
inhibit multiple receptor tyrosine kinases, which actively work for tumor growth, 
pathogenic angiogenesis and metastatic progression of cancer. Recently, in 2009, a 
novel scaffold developed by Pfizer, Toceranib (Palladia) (3) was approved by US-FDA 




extensive investigation in order to understand the SAR and biological activities, 






1.3.1 Spirocyclic scaffold in nature  
Spiro compounds are aromatic heterocyclic organic compounds with two ring 
systems. These rings are connected by a single (quaternary) carbon atom which is called 
as “spiro” carbon 
30
. 
Spirocyclic compounds are found in the structures of natural products such as 
alkaloids, lactones or terpenoids isolated from plants and living organisms. The way of 
action and the therapeutic promise for molecules containing spirooxindoles have been a 
major impulsive force in order to develop novel advance synthesis paths 
31
. Moreover, 
due to the fact that spiro linked carbon possesses tetrahedral scaffold, connected rings 




In 1900, Adolf von Baeyer created the first spiran and proposed nomenclature of 
bicyclic hydrocarbons as “spirocyclane” 
33
. Since then, spirocyclic heterocycles have 
been studied further to become drug candidates because of their important structural 
features and promising biological activity on pharmacological and therapeutical studies 
30,33
.  
In figure 1.5 spiro fused oxindole motifs from nature were indicated with the 
differences on their structures. As an example for spirocyclic scaffolds in nature, 
Coerulescine (4) was isolated from Phalaris coerulescens, blue canary grass and 
Horsfiline (5) was isolated from Horsfieldia superba Warb, Malaysian medical plant. 
These two examples show the simplest structure among the alkaloids. Nonetheless, they 
were excellent models to investigate novel compounds against human breast cancer 
cells 
34
. Spirotryprostatin A (6) and B (7), are indolic alkaloids isolated from the 




proved that they inhibit the G2/M progression of cell division in mammalian tsFT210 
cells (isolated from a mouse mammary carcinoma cell line). Therefore, they have great 
potential as anti-cancer drugs. By using these alkaloids, several compounds and 





Figure 1.5 - Spiro-fused oxindole motifs from nature emphasized their key moieties with two different 
colors (blue and orange), pink points indicate spiro carbons. 
 
The oxindole alkaloid, Alstonisine, (8) is extracted from the plant Alstonia 
acrophylla 
36
. Similar to Spirotryprostatin compounds (6-7), spiro-pyrrolidine core 
scaffold of Alstonisine, (8) was used as pioneer structure to develop new possible 
MDM2 inhibitor (MI-888 in figure 1.7) 
37
. Different from those, (+)-welwitindolinone 
A (9) is an antifungal alkaloid that has a spiro-fused cyclobutyl oxindole. It was isolated 
from the marine blue-green algea Hapalosiphon welwitschii and used against multiple 
drug resistance. (+)-welwitindolinone A (9) funtions as an anti-inflammatory agent 
while it is selective and potent p38α mitogen activated protein (MAP) kinase inhibitor. 
Lastly, Spirobrassinin (10) is a spiro-thiazolidinyl cruciferous phytoalexin which 







Due to its complex and challanging mechanism, cancer is one of the most 
important concerns among the global diseases. Investigations for new anti-cancer 
compounds are continuously improving in order to get more selective and less toxic 
compounds 
39
. Like most pharmaceuticals, nature is an important guide for 
spirooxindole scaffold in order to design and develop novel compounds. Special 
characteristics and complex structures show significant connection to their biological 
activities. With the help of synthetic chemistry, these features are simulated and 




1.3.2 Importance of Spirooxindoles 
Spirooxindoles are particular structures derived from a member of natural 
products spirooxindole alkaloids, tryptamine 
41
. According to studies, the core structure 
gives promising biological activities with spiro center fused at the C3 position on 
oxindole base with diverted functional groups attached 
42
. The spirooxindole moiety is 
responsible for several biological activities as anti-HIV, antimicrobial, antimalarial, 









In the literature there are several examples of spirooxindoles with different 
biological activities. One of them is spiro-cyclohexyl Satavaptan (11), a vasopressin  V2 
receptor antagonist, designed by Sanofi-Aventis and reported as an orally active and 




. Another example, is compound 
MI-888 (12), which is capable of achieving rapid, long-lasting and complete tumor 
regression as p53/MDM2 inhibitor with a Ki value of 0.44 nM in animal models of 
human cancer with oral administration 
39
. Additionally, Rhynchophylline (13) was 
described as an ion chanel blocker which mainly acts on cardiovascular and central 
nervous system diseases 
44
. NITD609 (14) is a potent anti-malarial compound as an 
alternative to artemisinin derivatives. Recently, spiro-tetrahydro-β-carboline NITD609, 
has completed Phase II clinical trials in humans 
45,38
. Moreover, antipyretic compound 
SPX_F (15) is showing significant activity against neuroinflammation 
4
. Spiro-










Repetitive presence of spirocyclic oxindoles in numerous natural products and 
biologically active molecules allowed them to become known and interesting synthetic 
targets 
39
. In the past decade spirocyclic oxindoles have increasing demand in industry 
and attention in academia for development of their synthesis 
4
. Based on the recent 
statistics, the number of publications has increased unprecedentedly since 2010 because 




Figure 1.8 - Number of publication for spirooxindoles between the years 2005 and 2015 (data 
taken from http://apps.webofknowledge.com/ in 2016). 
 
Lately, a remarkable number of investigations has done to synthesize variety of 
spiro-based compounds with promising biological activities. Reduced molecular 
flexibility gives conformational restriction to the molecule leading to better results in 
terms of biological activities 
38,32
. Taking into consideration the results of biological 
activity studies, the most frequently reported spirooxindole moieties in the literature are 








Figure 1.9 - Different spirooxindoles 17-20 with different activity against cancer. 
 
To date, several important compounds have been discovered and some are 
already on the process of clinical trials. For instance, as mentioned before, MI-888 (12) 
is capable of achieving rapid, complete and durable tumor regression on experiments 
with different models of human cancer with oral administration (Fig 1.7) 
46
. One of the 
examples, CFI-400945 (17), inhibitor of Polo-like kinase 4 (PLK4) (Ki= 0.26 nM) was 
recently reported as a first-in-class, potent, selective and orally active anticancer agent. 
The first-in-human phase I trial demonstrated positive anti-tumor activity for multiple 
tumor types establishing targeted safety, tolerability, and pharmacokinetics. CFI-400945 
(17) is considered a successful candidate for phase II trials 
47
. MI-219 (18) is an 
inhibitor of MDM2 presented by Feng et al. as a promising drug for the treatment of 
prostate cancer. The triple therapy with compound MI-219 (18), radiation and androgen 
deprivation therapy tumor growth, recurrence and death decreased significantly within 
the first 10 years of treatment 
48
. Additionally, with further improvements on 
pharmacokinetic profile of MI-219 (18) a new analog, SAR405838 (19), was 




tumor models. Recent publication from Wang et al. reported that SAR405838 (19) 
possess Ki= 0.88 nM to human MDM2 protein (is >10, >50 and >1,000-times more 
potent than MI-219 (18), nutlin-3a and the p53 peptide, respectively) with good 
chemical stability and oral bioavailability 
49
. Studies against GTL-16 human gastric 
carcinoma models published by Li et al. revealed that compound SMU-B is orally 
bioavailable showing significant tumor growth inhibition and pharmacodynamics effect 
50
. Finally, one of the potential analogs, RO8994 (20), is a new generation of p53-
MDM2 antagonists. RO8994 (20) was reported as a remarkable tumor growth inhibition 
in the wild-type p53 with IC50 of 5nM (HTRF binding assays) and 20nM (MTT 
proliferation assays) 
51
. These structures are potential clinical development candidates 
for the treatment of various human cancers. 
Focusing only in the anticancer properties of spirooxindoles, the diversity of 
heterocyclic motifs connected to C3 atom, 5 and 6 membered rings are the mostly 











This unique structure, spiro [pyrrolidine-3,3’-oxindole] 
4
 with 5 membered ring 
fused, is the focus of the new drug discovery and important synthetic targets because of 
its particular structure which possess a range of biological activities
52
. Their selectivity 
and low toxicity features are also approved as an advantage for their anti-cancer 




1.4 1,3,4-oxadiazole scaffold 
In pharmaceutical research area, heterocyclic ring systems have massive 
importance. One of the examples is oxadiazole (Fig 1.11), which includes in the 
chemical structure, two carbon atoms, two nitrogen atoms and one oxygen atom. Until 
now, oxadiazoles have already been used in different areas of medicine and pesticide 
chemistry. Additionally, they are used in material and polymer science. Recent reports 
took notice of 1,3,4-oxadiazoles cores as an important part of potential drug molecules. 
They have been frequently used as bioisosteric replacements for ester and amide 




Figure 1.11 - 1,3,4-oxadiazole. 
 
1,3,4-oxadiazole was prepared, for the first time by Ainsworth, in 1965. 
Recently several reports have disclosed the spatial characteristics of the 1,3,4-
oxadiazole scaffold and its importance in the medicinal chemistry 
54
. The importance of 
introducing 1,3,4-oxadiazole in drug discovery has several purposes. First of all, 1,3,4-
oxadiazole can be used as an essential part of the pharmacophore because it contributes 
favorably to ligand binding. Second, by the virtue of its flat and aromatic structure, 
substituents can be placed in very specific and appropriate positions 
53
. Consequently, 
the combination of 1,3,4-oxadiazole moieties with potential drug candidates leads to 
changes in compound flexibility and polarity. These combinations change the effect on 






Generally, a variety of disease areas are interested in including 1,3,4-oxadiazole moiety 






Figure 1.12 - Examples for 1,3,4-oxadiazoles in late clinical trials 53. 
 
There are some drugs in the market having 1,3,4-oxadiazole unit 
54
. Lately, 
AstraZeneca reported some examples of compounds containing an 1,3,4-oxadiazole 
moiety in the late stage clinical trials. In figure 1.12, two examples are included from 
different area of medicinal studies including oxadiazole scaffolds. Zibotentan (21) and 
Raltegravir (22) are already reported in the late stage clinical trials as anticancer agent 




1.5 Scope of the thesis 
Previous work from our research group was focused on the development of 
novel spirooxindole scaffolds to modulate p53 activity. The first spirooxindole core 
developed was a structural analog of the spiro pyrrolidine oxindole scaffold present in 
the p53-MDM2 interaction inhibitor 23. In this scaffold the pyrrolidine ring was 
replaced by an isoxazoline ring 
57
. The synthesized compounds were shown to possess 
anticancer activity by disrupting the interaction between p53-MDM2, being compound 
23 the most active in this series 
56






Figure 1.13 - Example of previously studied spiroisoxazoline oxindoles 56 
 
Further, optimization of spiroisoxazoline oxindoles led to the spiropyrazoline 
oxindole scaffold 24, which contains a nitrogen atom instead of an oxygen in the five 
membered ring (Fig 1.14) 
13
. This change allowed to have one additional aromatic 
substituent (N-Ar) on the scaffold. Most compounds exhibited an increase of activity as 
anticancer agents comparing with the corresponding spiroisoxaline oxindoles. 
Moreover, compound 24 showed selectivity against MCF-7 over MDA-MB-231 breast 
cancer cell and the non-tumor HEK cell line. 
 
Figure 1.14 - Example of previously studied spiropyrazoline oxindoles 13 
 
 
Based on positive results of 23 and 24, another study was investigated for a 
novel library of spirooxadiazoline oxindoles 
13,57,56
. In the new presented scaffold 25, 
five membered ring included [1,2,4]-oxadiazole core (Fig 1.15). This change revealed 





 positions of the oxindoles and meta-halogens in both phenyl rings. 












Figure 1.15 - Example of previously studied spirooxadiazoline oxindoles. 
 
Following these studies, in the present thesis, we aimed to develop a novel 
library of spirooxindole derivatives to be evaluated as potential anti-cancer agents. To 
date, no study has discussed the synthesis and the biological activities of 3',5'-diphenyl-
spiro[indoline-3,2'-[1,3,4]oxadiazoline]-2-one. Particularly, we intended to synthesize a 
novel library of compounds based on [1,3,4]-oxadiazole core and to diversify them by 
using different substituents on the phenyl rings (Fig 1.16). Compounds were further 
























































2 Results and Discussion 
2.1 Synthesis of a library of spirooxadiazoline oxindoles 
Spirooxadiazoline oxindoles result from the combination of two potential anti-
cancer scaffolds; oxadiazoline and oxindole. Oxadiazoline has been analyzed in various 
new synthesis methods for different pharmaceutical applications. Among the four 
possible isomers of oxadiazole, 1,3,4-oxadiazole is the most important in medicinal 
chemistry due to its various biological activities. Present in several drugs, it became an 
important scaffold for the development of novel drugs 
54
. Oxindole exists widely in 
tissues and fluids of mammals as well as in natural products extracted from a variety of 
plants, bacteria and invertebrates. They possess a diverse pharmacological profile due to 
the extensive range of biological activities 
27
. Spirooxadiazoline oxindoles containing a 
[1,2,4]oxadiazoline ring have already been studied in our research group. Based on the 
promising results obtained in our research group analysis with five membered ring 
spirooxindoles, in this thesis we decide to expand further these studies. For the first time 
a library of novel of spiro-oxindoles containing a [1,3,4]oxadiazoline ring was 
synthesized and evaluated as potential anti-cancer agents. 
In this thesis, spiro[indoline-3,2'-[1,3,4]oxadiazoline]-2-ones 32 synthesized 
with different substituents on phenyl groups in 3’ and 5’ positions and Cl or Br 
substituted on positions 5, 6 and 7 of the oxindole ring. Diversity was acquired by using 
different substituted aromatic aldehydes and arylhydrazines for the synthesis of the 
intermediaries. Additionally, commercially available derivatives of isatin were used for 
the final reaction. Retrosynthetic studies helped to construct the method of synthesis of 





Scheme 1 - Retrosynthetic analysis of spirooxadiazolines. 
 
Spirooxadiazoline oxindoles 32 were synthesized by 1,3-dipolar cycloaddition 
between isatin derivatives 31 and nitrile imines 30 (formed in situ from hydrazonyl 
chlorides 29). Hydrazonyl chlorides 29 were synthesized using the procedure reported 
by Patel 
59
 and starting from hydrazones 28 (synthesized using the procedure reported 
by Hwu 
60
). The synthetic scheme is shown below (Scheme 2). 
 
 
Scheme 2 - Synthetic scheme to obtain spirooxadiazoline oxindoles 32. Reaction conditions: i) EtOH, rt; 





2.1.1 Synthesis of hydrazones 
 
 
Scheme 3 - General reaction for the synthesis of hydrazones 28a-h. 
 
Substituted hydrazones 28a-h were prepared by condensation reaction of 
phenylhydrazine derivatives 26 with benzaldehyde derivatives 27 in aqueous ethanol 
20% 
60
. This core structure is a nitrogen-centered radical and it has been proved that can 




H NMR spectra of intermediates 28 were in 





Scheme 4 – Reaction mechanism for the synthesis of hydrazones.  
 
Reaction mechanism is detailed in Scheme 4. The reaction involves the 
nucleophilic attack of the lone pair of electrons of one of the nitrogens of the hydrazine 
to the carbonyl carbon. Correspondingly, the desired hydrazone is obtained after the 








  Table 1 - Scope of hydrazones and their yields. 
Compounds R2 R3 Yield 
28a H H 75% 
28b m-Cl m-Cl 95% 
28c p-MeO H 72% 
28d p-Cl H 96% 
28e H m-Cl 89% 
28f H o-Cl 92% 
28g m-Cl o-Cl 90% 
28h H p-Cl 92% 
      
                  




Reactions of hydrazones 28a-h were relatively fast (2-3h), performed in the dark 
at room temperature and gave excellent yields (72-96%) (Table 1). In the literature, 
yields of reference compounds indicated between 71-92% 
60
.  
The synthesized compounds 28a-h were characterized by NMR. A typical 
1
H-
NMR spectrum of compound 28a-h is exemplified by compound 28a. The N-H 
resonance signal is a broad singlet signal on lower field of spectrum (8.57 ppm). The 
resonance signal of N-H proton with no substituent hydrazone 28a is at 7.45 ppm. 
While for other hydrazones with substituents (28b-h) appeared as a broad singlet in a 
range between 7.70 - 9.70ppm. The general distribution of proton chemical shifts 
indicates that aromatic group protons are displayed between 6.30 – 8.30 ppm 
65
. All 
synthesized hydrazone derivatives in the first step had two aromatic rings and, as 
expected, their signals were confirmed in the aromatic range of the NMR spectrum. In 
addition to the aromatic protons, another non-aromatic significant signal was one of the 
least shielded hydrogen from CH=N. This vinylic proton mostly overlapped with the 
resonance signals of phenyl ring B2 and B6 protons and gave multiplet signal around 
7.71-7.55 ppm for compounds 28a, 28c and 28e. On the other hand, the rest of the 
hydrazones, proton from CH=N showed singet signal. Additionally, a characteristic 
singlet at 3.82 ppm indicative of a -OMe group, was also on upper field on NMR 








Figure 2.1 – a) 
1
H-NMR spectra for compound 28a with the enlargement of the spectra. b) 
1
H-




In the figure 2.1, are shown the difference between NH and CH=N chemical 
shifts for compounds 28a and 28e. For compound 28e, meta positioned halogen 
displayed inductive effect on the NH proton and signal appeared at 9.67 ppm (Fig 2.1). 
The proton signal for compound 28a was at 7.60 ppm. The proton of CH=N was 




Figure 2.2 - 
13




C-NMR spectrum characteristic methine carbon connected to nitrogen 
gives a signal at 137.41 ppm for compound 28a. All the other hydrazone derivatives 
display small difference with carbon chemical shifts pending the substituents on their 
aromatic moiety. Carbons that can give different peaks were mainly the ones that have 
substituents. For example, when aromatic substituent -OMe was para positioned 28c, 
carbon that was connected to –OMe, displayed a strong paramagnetic effect at 160.10 
ppm. However, without any substituent same carbon gave a signal at 128.55 ppm. In the 
figure 2.2, presented carbon peaks are corresponding with the reported results in the 
literature 
62,63







2.1.2 Synthesis of hydrazonyl chlorides 
 
Scheme 5 - General reaction of hydrazonyl chlorides 29a-h. 
 
Hydrazonyl chlorides 29a-h were synthesized by reacting the appropriate N-
arylhydrazones with N-chlorosuccinimide-dimethyl sulphide complex, which was 
prepared in situ at -78ºC 
59,61
.  
Hydrazonyl chlorides are widely used with oxindoles in 1,3-dipolar cyloaddition 
reactions which is one of the most chosen methods for 5 membered ring formation. In 
order to perform the chlorination, the respective hydrazone was prepared by using N-
chlorosuccinimide and dimethyl sulfide complex which is known as Corey-Kim reagent 
66
. As mentioned in the literature, N-chlorosuccinimide-dimethyl sulfide is a very 
reactive complex and is stable only at low temperatures. Nevertheless, reaction between 
hydrazone and Corey-Kim reagent occurs under extremely mild conditions and can be 
prepared in situ by an inexpensive method. Besides, this method was reported in good 




Scheme 6 - Detailed mechanism of hydrazonyl chloride reaction a) CH2Cl2 b) Cl
 
 
Initially, the halosulfonium salt was formed by N-chlorosuccinimide and 




group. Next, the nucleophilic attack leads up from the acidic N-H of hydrazone to give 
intermediate form of N-chlorosuccinimide. Sulfur with cation ion is more electrophilic 
and not willing to stay connected to the nitrogen, therefore electron from the neighbor 
double bond helps dimethylsulfide group to leave and forms the stable cation on carbon. 
The stable cation undergoes attack by the Cl- to form alkyl halide compound. The 
reason why benzylic cation is more stable is explained with the presence of adjacent 
nitrogen atom. This cation can give phenylazobenzyl chloride which after tautomerise to 





  Table 2 - Scope of hydrazonyl chlorides and their 
yields. 
Compounds R2 R3 Yield 
29a H H 69% 
29b m-Cl m-Cl 61% 
29c p-MeO H 58% 
29d p-Cl H 83% 
29e H m-Cl 48% 
29f H o-Cl 92% 
29g m-Cl o-Cl 90% 
29h H p-Cl 92% 
     
 
           
         





The products were obtained in moderate to excellent yields (48-92%). The 







H-NMR spectrum of hydrazonyl chlorides are relatively similar to the ones 
obtained for the corresponding hydrazones but with one less proton signal because of 
the Cl addition. Nevertheless, the presence of a chlorine atom shielded signals of H-B2 
and H-B6 comparing the same positioned protons NMR spectra of hydrazonyl chloride 








Figure 2.3 - 1H-NMR spectra of hydrazone (28a) overlapped with spectra of hydrazonyl chloride(29a). 
 
In order to understand the differences, both hydrazone 28a and hydrazonyl 
chloride 29a NMR spectra examples were overlapped as seen in the above image (Fig 
2.3). The 
1
H NMR spectrum confirmed the difference when Cl atom is connected to the 
carbon of CH=N 29a or not 28a. Overall, vicinal protons in both compounds are the 
only and the most affected ones. For example, the single proton of N-H appeared as a 
broad singled but it was shifted downfield and gave signals between 8.00-9.00 ppm. 




appeared more shielded than the proton of N-H and gave doublet signal instead of 
multiplet. This was also because of the absent proton connected to the imine carbon. For 
instance, -OMe protons from the compound 29c did not show big differences when it 
was compared with protons from the compound 28c. A characteristic singlet of -OMe 
group for compound 29c determined at 3.90 ppm, so signal moved slightly to lower 
field on NMR spectrum, but it was still the most shielded one. 
The 
13
C NMR spectra confirmed the presence of two aromatics and an imine 
group. They revealed the presence of 13 carbon signals, comprising three quaternary 
carbons (two aromatic sp3 carbons at 172.0 ppm and 174.2 ppm, ten carbons appear at 
71.4 ppm, one imine at 42.6 ppm). Comparing with 
1
H-NMR spectra, observed signals 
in 
13
C-NMR spectra for hydrazone and hydrazonyl chloride also did not give surprising 
changes. The visible difference in chemical shift was mainly for the quaternary carbon 
CCl=N 
61
. For the other hydrazonyl chlorides the results were also consistent (see 
experimental procedure). 
2.1.3 Synthesis of 3',5'-diphenyl-spiro[indoline-3,2'-
[1,3,4]oxadiazoline]-2-one 
 
Scheme 7 - Synthesis of spirooxadiazoline oxindoles 32a-l. 
 
Cycloaddition reaction of nitrile imine to C=O groups was indicated as a 
successful method for oxadiazole formation. Different methods have been reported for 
the synthesis of spirooxindole scaffold until now, however there is still limited research 
for spirooxindoles containing an oxadiazoline moiety 
67
. One of the examples is the 
reaction of isatin with carbohydrazine 
68
 and the other is with cyanoacetic acid 
hydrazine 
69




disadvantages such as, moderate yield of products, extended reaction time, difficult 












32a 5-Cl H H 78% 
32b 7-Br H H 46% 
32c 6-Cl H H 54% 
32d 7-Cl H H 57% 
32e H H H 90% 
32f 5-Br H H 77% 
32g 6-Cl H p-MeO 67% 
32h 6-Cl m-Cl m-Cl 42% 
32i 5-Br m-Cl m-Cl 58% 
32j 5-Cl m-Cl m-Cl 75% 
32k 5-Cl H p-Cl 69% 
32l 5-Br H p-Cl 66% 
32m 6-Cl p-Cl H 35% 
32n H H m-Cl 49% 
 
In this study, we extended the scope of this reaction with different isatins 31a-l 
and hydrazonyl chlorides 29a-h. As a result, the corresponding spirooxindoles 32a-l 
were synthesized from moderate to high yields (Table 3). Therefore, spirooxadiazoline 
oxindoles were synthesized by using a simple and efficient method; 1,3-dipolar 
cycloaddition reaction between indoline-2,3-diones 31a-l and hydrazonyl chlorides 29a-
h in the presence of Et3N in CH3Cl2 at room temperature. The comparison with the 
other methods indicates advantages of this method namely, using available starting 








Scheme 8 - Mechanism of spirooxadiazoline reaction. 
 
Reactions in the thesis have been performed by isatin derivatives and after 
spirooxindole structure formation, oxindole motif existed in the final scaffold. Isatins 
include multiple bond system, namely “dipolarophile” and hydrazonyl chloride 
derivatives are zwitterionic in all-octet resonance structures 30 which are seen 
ambivalent on 1- and 3-positions, namely “dipole”. These structures show both 
electrophilic and nucleophilic activity. 1,3-dipolar cycloaddition reaction, which is also 
known as [3+2] cycloaddition leads to 5-membered heterocycles with remarkably wide 
range of utility in the synthesis (Scheme 9). 
 





The reaction starts in the presence of the base, triethylamine, added to a mixture 
of hydrazonyl chloride and isatin in dichloromethane. Base abstracts the proton of 
nitrogen from the corresponding hydrazonyl chloride and undergoes to the formation of 
nitrile amine, which is generated in situ. After 1,3-dipolar cycloaddition reaction takes 
place and formed the 5 membered oxadiazoline ring (Scheme 10). The reaction took 
place at room temperature for 16h (overnight) to afford 3',5'-diphenyl-spiro[indoline-
3,2'-[1,3,4]oxadiazoline]-2-one in 78% yield. 
This year, Alizadeh et al. published the same spirooxindole scaffolds as 
combination of spirooxindole and [1,3,4]-oxadiazole structures 
67
. The paper was 
focused on the synthesis of spiro[1,3,4]-oxadiazoline oxindoles, but biological studies 
were not performed. 
 
Figure 2.4 -1H-NMR spectrum of compound 32a in acetone-d6 and numbered structure. (Full spectra is 




H-NMR spectra of compound 32a was performed and is presented in the 
figure 2.4. The NH proton signal showed up on the lower field of the spectrum. 
Comparing with the respective hydrazonyl chloride, the final compound 32a showed an 
increase of aromatic porton signals, which suggests that 1-3 dipolar cycloadditon 
reaction occurred. Analyzing the 
1
H-NMR spectrum, the presence of the cloro atom in 
the 5
th
 position of the oxindole ring gave vicinal hydrogen C4 on the less shielded field, 
determined at 7.62 ppm. Other protons are C6 and C7 which were more shielded and 
determined at 7.16 ppm and at 6.85 ppm respectively. Moreover, as mentioned before 




were on the aromatic rings, did not appear so different from the signals of 
corresponding hydrazonyl chloride. 
 
 










C NMR and HMQC spectra confirmed the presence of the spiro, carbonyl, 
nitrile and two aromatic groups. In order to confirm the position of carbons HMQC 
spectrum assisted to clarify aromatic and especially the isatin core carbons (Figure 2.5). 
For compound 32a, they revealed the existence of 21 carbon signals, comprising eight 
quaternary carbons; spiro carbon at 95.7 ppm, two aromatic carbons at 129.0 ppm and 
143.1 ppm, one carbon on oxadiazoline core at 152.7 ppm, carbonyl carbon at 171.6 
ppm, two carbons on indoline core at 126.6 ppm and 142.4 ppm and carbon on aromatic 
ring of indoline 125.7 ppm. Additionally, thirteen methines on aromatic rings appeared 
between 113.8 – 133.4 ppm (Figure 2.6).  
 
 
Scheme 10 - Regioselectivity of 1,3-dipolar cycloaddition reactions with spirooxadiazoline oxindoles. 
Stereochemistry is necessary for pharmacology and has a huge impact on 
ADME of therapeutic molecules 
39
. Taking into consideration the stereoselectivity of 
1,3-dipolar cycloaddition reactions, there are two possible regioisomeric oxadiazoline 
formations based on the electronic and steric effects of reactants. Nevertheless, based on 
following collected data, we confirmed that the regioisomer obtained was the 
spiro[indoline-3,3’-[1,3,4]oxadiazoline]-2-one. First, when the vicinal atoms are oxygen 
and nitrogen, the 
13
C NMR spectrum indicated that spiro carbon signal was observed 
around 96.04 ppm. Furthermore, searching through the literature, in the oxadiazoline 
ring the chemical shift of the carbon is around 150.0 ppm but for similar spiro 





. For the alternative regioisomer with vicinal atoms are oxygen and carbon, the 
13
C 
NMR spectrum indicates that spiro carbon signal shows up around 87.6-89.8 ppm 
70
. 
Additionally, chemical shift of carbon atom from oxadiazoline C=N appeared around 
152.0-155.0 ppm whilst in literature 155.4-157.0 
71
 (Scheme 11). This difference is 























2.2 Biological Evaluation 
2.2.1 Cellular activity and structure-activity relationships (SAR) 
 
The anti-proliferative activity of compounds 32a-r was tested in vitro against 
different cancer cell lines: an isogenic matched pair of wild type p53 and deleted human 




], and human colorectal 









Twelve compounds were synthesized with different substituents attached to the 
spirooxadiazoline oxindole core structure and tested for their biological anti-tumor 
activity. Results are reported in detail below for compounds 32a-l.  
 
Introduction of electron-withdrawing halogens on the benzene ring of indolin-2-





. However, they were non-cytotoxic at concentrations up to 50 µM. 
The activity varied with the difference in position of substituents of the indolin-2-one. 









32a 5-Cl H H 
32b 7-Br H H 
32c 6-Cl H H 
32d 7-Cl H H 
32e H H H 
32f 5-Br H H 
32g 6-Cl H p-MeO 
32h 6-Cl m-Cl m-Cl 
32i 5-Br m-Cl m-Cl 
32j 5-Cl m-Cl m-Cl 
32k 5-Cl H p-Cl 

















































































Figure 2.7 - Cell Viability (%) determined by MTS method after 72h in cell lines with p53 (HCT p53+/+) and 
without p53 (HCT p53-/-). Results are given in % relative to control and represent means with 95% confidence 
intervals of three independent experiments performed in triplicate and carried out independently. 
 
Based on the first screening, eight compounds did not show any significant 
activity for the cell line with p53 (HCT116 p53
+/+
). Only compound 32g showed more 
potency and decreased the cell viability more than the other compounds but viability 
was still above 50% even with 50 µM concentration. Similar results were obtained for 
compounds tested in HCT116 p53
-/-
 cancer cell lines. As seen in the figure 2.7, almost 




However, none of them decreased viability below 50% with 5-fold and 10-fold increase 
in concentration.  
All compounds tested against HCT116 p53
+/+
 and HCT116 p53
-/-
 cancer cell 
lines were not active up to 50 µM and a lack of selectivity was observed between these 
cancer cell lines. On the other hand, interestingly there was no growth or specific 










































Figure 2.8 - Cell viability (%) determined by the MTS method after 72h of exposure. Results are given in % relative 
to control and represent means with 95% confidence intervals of three independent experiments performed in 
triplicate and carried out independently. 
 
 
Compounds 32a-h were more active for SW620 cell lines than in both HCT cell 
lines. Moreover, three of these derivatives 32a, 32b, 32e, 32f had higher activity then 
the others (Fig 2.8). As common feature, all these compounds, do not have any 
substituents on respective aromatic rings but oxindole ring was substituted with Br or Cl 
in different positions. Comparing anti-tumor activities for compounds 32a, 32b, 32e, 
32f, three independent experiments were performed in triplicate and carried out 





32b in SW620 cell line















      
32e in SW620 cell line
















Figure 2.9 – Cell viability (%) for compounds 32b and 32e in SW620 cell line for 72h of exposure. Results are 
given in % relative to control and represent means with 95% confidence intervals of three independent experiments 
performed in triplicate and carried out independently.  
 
As seen in the figure 2.9 viability decreased as desired and IC50 values of these 
compounds were calculated. Compounds 32b and 32e possessed Br and Cl in positions 
7 and 6 of the oxindole respectively and no substituents on the other aromatic rings. For 
compound 32b and 32e IC50 values were calculated as 26.47 µM and 7.98 µM. 
However, it was proved that it has potential on mutated cancer cell lines and this will be 
further investigated in future studies. 
 
32a in SW620 cell line















      
32f in SW620 cell line
















Figure 2.10 - Cell viability (%) for compounds 32a and 32f in SW620 cell line for 72h of exposure. Results are 
given in % relative to control and represent means with 95% confidence intervals of three independent experiments 
performed in triplicate and carried out independently. 
 
Compounds 32a and 32f have the highest activity against SW620 cancer cell 
line (Fig 2.10). Remarkably, compounds showed the best potent having the IC50 values 
of 6.42 µM for 32a and 4.59 µM for 32f. Both scaffolds have halogen in position 5
th
 of 




compounds (32a) was further investigated in CCD-18Co human normal colon 















































Figure 2.11 - Cell viability (%) for compound 32a in SW620 and CCD-18Co cell lines for 12.5 µM and 72h of 
exposure. Results are given in % relative to control and represent means with 95% confidence intervals of three 
independent experiments performed in triplicate and carried out independently. 
 
Noteworthy, results confirmed that with four different concentrations, 32a did 
not result in any toxicity against normal colon cell CCD-18Co up to 50 µM (Fig 2.11). 































































Figure 2.12 - Cell viability (%) screening for compounds 32n, 32o, 32p, 32r in HCT p53 +/+ and SW620 cell 
line for 72h of exposure. 
 
After having the best results for compounds 32a and 32f, which were Cl and Br 
substituted on the 5
th
 position of oxindole core, more derivatives were synthesized and 
screened to test their biological activities. Therefore, compounds with Cl or Br 
substituted on the 5
th
 position of oxindole core remained same for all derivatives but 
substituents on aromatic ring were changed. Compounds 32i, 32j, 32k and 32l were 
recently tested in SW620 and HCT116 p53
+/+
 cell lines with only two different 
concentrations. The aim of this test was to screen the potential of new compounds in 
these different cell lines. HCT116 p53
+/+
 was chosen in order to understand if the 
derivatives of compounds are also only active against mutated cell lines. Regarding the 
HCT116 p53
+/+
 cell viability, results were as expected and none of the tested 
compounds revealed activity up to 20 µM. On the other hand, the compounds displayed 
remarkably low cell viability on mutated cell line, SW620, not only for 20 µM but also 
for 10 µM concentrations used. Since there were not enough replicates of this 
experiment, IC50 value was not possible to calculate. However, these high potential anti-







SAR analysis was concluded as seen below in order to have an idea about the key parts 
of the compounds for their activity (Fig 2.13). 
 
 













































In conclusion, in this thesis new libraries of spiro[indoline-3,2’-[1,3,4]oxadiazol]-2-
ones were synthesized from the reaction of isatin derivatives and hydrazonyl chlorides 
by using the 1,3-dipolar cycloaddition reaction. 
On the way of discoveries for a new generation of effective and potential anti-
cancer compounds, spirooxadiazoline oxindoles have come out with their spatial 
scaffolds and potential biological activity. In this thesis for the first time oxindole 
moeity was merged with [1,3,4]-oxadiazoline moeity. Reactions were successful and 
completed with high yields. Moreover, compounds were tested in vitro against different 
cancer cell lines: an isogenic matched pair of wild type p53 and deleted human 
colorectal cancer cell lines [HCT116 p53
(+/+)
 and HCT116 p53
(-/-)
], and human 
colorectal adenocarcinoma cell lines [SW620 (mut p53)]. Results obtained 
demonstrated that compounds 32a-h display activity against SW620 (mut p53) cell 
lines. Specifically, compounds 32a, 32e and 32f showed remarkable results with IC50 
6.42 µM, 7.98 µM and 4.59 µM respectively. Besides, in order to determine if 
compounds are toxic against normal cell lines, compound 32a was tested in CCD-18Co 
human normal colon fibroblasts. Results revealed no toxicity. Compound 32a was 
confirmed by having a high activity against SW620 cancer cell lines whilst having no 
toxic impact on normal fibroblast cells. Additionally, according to screening tests 
against HCT p53
+/+
 and SW620 cell lines, compounds 32i-l showed high anti-cancer 
potential against SW620 cell lines more than HCT p53
(+/+)
. However, these results must 
be further investigated. As a result, compounds showed more activity in mutated 
SW620 cell line than others. The mechanism of action is perhaps working in the 
mutated form, so extented library of spirooxadiazolines can be further tested to improve 
the antiproliferative activity in mutated SW620 cell line. Besides, compounds with the 
best activity against cancer cell lines were with Cl or Br substituted on their oxindole 
core.  
According to the promising results that are reported in this thesis, in terms of 
future directions, a new library can be sythesized with the indoline-2,3-diones Cl or Br 






 position has been reported 
72, 73
. Based on good results from in vitro studies, 
increase in potency was obtained without any substituents on aromatic rings. However, 
combining 5-Cl or 5-Br isatins with different hydrazonyl chlorides with variety of 
halogens or more bulky groups on phenyl groups should be evaluated to get more 
interesting results. Besides, best compounds can be tested in different cancer cell lines 
in order to see the difference in activity. Additionally, we performed the first screening 
in mutated cell line SW620 for compounds 32i, 32j, 32k and 32l which showed a 
promising decrease in viability. Still further experiments have to be performed to 































































4 General Methods 
4.1 Reagents and Equipment 
Reagents and solvents were obtained from commercial suppliers and used with 
no further purification. The solvents were of analytical grade and in most cases dried by 
distillation when the reaction conditions required a dry solvent. DCM was dried by 
distillation from calcium chloride. The water used in reactions and preparation of 
preparative was purified in the laboratory. All deuterated solvents were purchased from 
Sigma-Aldrich.  
For monitoring the reactions, analytical thin layer chromatography Analysis 
Merck Silica Gel 60 F254 aluminum plates were used. The plates were visualized using 
UV light. For purification, flash column chromatography with Merck Silica Gel (200- 
400 mesh) silica were used. In order to obtain a finer purification, glass plates coated 






C NMR spectra were recorded on a Bruker 300 Ultra-Shield. 
1
H 
nuclear magnetic resonance spectra were recorded at 300 MHz and 
13
C nuclear 




C NMR chemical shifts 
are reported in parts per million (ppm, δ) referenced to the solvent used and the proton 
coupling constants J in hertz (Hz). Multiplicities are given as: s (singlet), bs (broad 
singlet), d (doublet), dd(doublet doublet), t (triplet), dt (doublet triplet), q (quartet), m 
(multiplet). Spectra were assigned using appropriate COSY, DEPT, HMQC and HMBC 
sequences. Elemental analysis was performed in a Flash2000 ThermoScientific 
elemental analyzer and are within ±0.4% of theoretical values. Mass spectra were 
analyzed using MassLynxV 4.1 software. For determination of melting points Kofler 
camera Bock monoscope M. was used. 
Besides, the synthesis of compounds 28d-h and 29d-h used for the synthesis of 








4.2 Synthetic Procedure and Product Characterization 
4.2.1 General procedure for the synthesis of hydrazones (28a-h) 
A phenylhdrazine derivative (1.0 equiv) was mixed with benzaldehyde 
derivative (1.2 equiv) in aqueous ethanol 20% (2mL/mmol of phenylhydrazine) and 
stirred at room temperature in the dark for 2-3 hours. The precipitate formed was 
filtered and washed with aqueous ethanol 20%. For the synthesis of compounds 28b, 
28e and 28h, the phenylhydrazine used was in hydrochloride form, so it was necessary 
to add triethylamine (1.0 equiv) 15 minutes before adding the corresponding 
benzaldehyde (adapted from 
60





4.2.1.1 Synthesis of 1-benzylidene-2-phenylhydrazine (28a) 
 
Synthesized according to the general procedure; 2.35 g benzaldehyde (18.49 
mmol, 1eq.) was mixed with ethanol (20%) (40 ml). Then 2.0 mL phenylhydrazine 
(22.19 mmol, 1.2eq.) was added. Synthesized according to the general procedure, 
compound 28a was obtained as a brown solid (2.7 g, 76 % yield). 
MP: 156-158 ºC (mp lit. 154 ºC 
62




H NMR (400 MHz, CDCl3) δ (ppm): 7.70 – 7.62 (m, 3H, 
CH=N, H-B2,6), 7.60 (br s, 1H, NH), 7.45 – 7.35 (m, 2H, H-
B3,5), 7.35 – 7.24 (m, 3H, H-B4, H-C3,5), 7.13 (dd, J = 8.5, 1.0 Hz, 2H, H-C2,6), 6.96 – 
6.85 (m, 1H, H-C4). NMR spectra are in accordance with the ones described in the 








4.2.1.2 Synthesis of 1-(3-chlorobenzylidene)-2-(3-chlorophenyl)hydrazine 
(28b) 
 
Synthesized according to the general procedure; 1.041 g 3-Cl phenylhydrazine 
(5.585 mmol, 1eq.) was mixed with ethanol (100%) (this time without water) (2.4 ml) 
and 0.76 mL TEA were added to mixture. After 0.76 mL 3-Cl benzaldehyde (6.702 
mmol, 1.2eq.) was added to the mixture. Synthesized according to the general 
procedure, compound 28b was obtained as a light pink solid (1.4 g, 95 % yield). 
Mp: 98-100 ºC; 
1
H NMR (300 MHz, CDCl3) δ (ppm):7.70 
(br s,1H, NH), 7.66 (s, 1H, H-B2), 7.62 (s, 1H, CH=N), 7.50 
(dt, J = 6.9, 1.8 Hz, 1H, H-B6), 7.35 – 7.27 (m, 2H, H-B4,5), 
7.22 – 7.15 (m, 2H, H-C2,5), 6.92 (ddd, J = 8.2, 2.1, 0.9 Hz, 
1H, H-C6), 6.85 (ddd, J =8.1, 2.1, 1.0 Hz, 1H, H-C4). NMR spectra are in accordance 





4.2.1.3 Synthesis of 1-(4-methoxybenzylidene)-2-phenylhydrazine (28c) 
 
Synthesized according to the general procedure; 1,00 g phenylhyrazine 
(9,25mmol, 1eq.) was added to 1,35 mL 4-OMe benzaldehyde (11,1 mmol, 1.2eq.). 
After ethanol (20%) (20,11 ml) was added to mixture.  
Synthesized according to the general procedure, compound 28c was obtained as a light 
pink solid (3592.3 mg, 72 % yield). 
Mp: 116-118 ºC (mp lit. 115 ºC 
75




H NMR (300 MHz, CDCl3) δ (ppm): 7.63 – 7.54 (m, 
3H, CH=N, H-B2,6), 7.46 (br s, 1H, NH), 7.31 – 7.21 (m, 
2H H-C3,5), 7.12 – 7.05 (m, 2H, H-C2,6), 6.93 – 6.88 (m, 
2 H-B3,5), 6.88 – 6.81 (m, 1H, H-C4), 3.82 (s, 3H, OCH3). NMR spectra are in 











4.2.2 General procedure for the synthesis of hydrazonyl chlorides 
(29a-h) 
To a solution of N-chlorosuccinimide (NCS) (3.0 equiv) in dichloromethane 
(DCM) (3.5 mL/mmol of hydrazone) at 0 °C was added dimethyl sulfide (DMS) (6.0 
equiv) over 5 minutes. After stirring for 15 minutes, the reaction was further cooled to –
78 °C. Then the corresponding hydrazone 28a-h (1.0 equiv) dissolved in CH2Cl2 (1 
mL/mmol of hydrazone) was added. The reaction was stirred at –78°C for 1h, and then 
slowly allowed to warm to room temperature over 3 h. The reaction was quenched by 
addition of cold water. The organic layer was then washed with brine (1x), saturated 
sodium sulfite aqueous solution (2x), and water. The organic layer was dried over 
anhydrous Na2SO4, filtered, and concentrated to afford the corresponding hydrazonoyl 
halide (adapted from 
59,61
). For characterization, chloroform-d was used as a solvent. 
 
4.2.2.1 Synthesis of N'-phenylbenzohydrazonoyl chloride (29a) 
 
Mixed of NCS (4,086 g) with DCM (41,36 mL) at 0⁰C in ice bath. Then added 
DMS (5,63mL) over 5 minutes. After stirring for 15 minutes, the reaction was further 
cooled to -78⁰C and hydrazone (2,0084g) was added.  
Synthesized according to the general procedure, compound 29a was obtained as a 
brown solid (1612.2 mg, 69 % yield). 
Mp: 128-130 ºC (mp. lit 129-130 ºC 
76





NMR (400 MHz, CDCl3) δ (ppm): 8.05 (br s, 1H, NH), 7.96 
– 7.89 (m, 2H, H-B2,6), 7.46 – 7.35 (m, 3H, H-B3,4,5), 7.35 – 
7.28 (m, 2H, H-C3,5), 7.22 – 7.15 (m, 2H, H-C2,6), 6.95 (t, J 
= 7.3 Hz, 1H, H-C4). 











4.2.2.2 Synthesis of 3-chloro-N'-(3-chlorophenyl)benzohydrazonoyl 
chloride (29b). 
 
Mixed of NCS (1,81 g) with DCM (18,3 mL) at 0⁰C in ice bath. Then added 
DMS (2,0 mL) over 5 minutes. After stirring for 15 minutes, the reaction was further 
cooled to -78⁰C and hydrazone (1,2 g) was added. 
Synthesized according to the general procedure, compound 29b was obtained as a dark 
brown-reddish solid (1648.7 mg, 61 % yield). 
Mp: 52-54 ºC; 
1
H NMR (300 MHz, CDCl3) δ (ppm): 8.08 
(br s,1H, NH), 7.91 – 7.87 (m, 1H, H-B2), 7.83 – 7.77 (m, 
1H, H-B6), 7.38 – 7.33 (m, 2H, H-B4,5), 7.24 – 7.17 (m, 2H, 
H-C2,5), 7.04 – 6.98 (m, 1H, H-C6), 6.93 (ddd, J = 8.0, 1.9, 
0.9 Hz, 1H, H-C4). NMR spectra are in accordance with the ones described in the 
literature for this compound 
61
. 
4.2.2.3 Synthesis of 4-methoxy-N'-phenylbenzohydrazonoyl chloride 
(29c). 
 
Mixed of NCS (3,56 g) with DCM (35,73 mL) at 0⁰C in ice bath. Then added 
DMS (3,9 mL) over 5 minutes. After stirring for 15 minutes, the reaction was further 
cooled to -78⁰C and hydrazone (2,00 g) was added. 
Synthesized according to the general procedure, compound 29c was obtained as a dark 
brown semi-solid (1431.2 mg, 58 % yield). 




H NMR (300 MHz, CDCl3) δ (ppm): 9.89 (br s, 1H, 
NH), 7.87 – 7.82 (m, 2H, H-B2,6), 7.36 – 7.30 (m, 2H, 
H-C3,5), 7.21– 7.18 (m, 2H, H-C2,6), 7.04 – 6.98 (m, 2H, 
H-B3,5), 6.82 – 6.75 (m, 1H, H-C4), 3.90 (s, 3H, OCH3). NMR spectra are in accordance 














A solution of a corresponding hydrazonyl chloride (2.0 equiv) in DCM (1 
ml/mmol of isatine) was added to corresponding isatine (1.0 equiv) in the room 
temperature and under argon atmosphere. The reaction was stirred for 15 mins before 
addition of TEA (2.0 equiv). TEA was added in a dropwise manner. After addition 
completed, reaction stirred overnight under argon atmosphere until total consumption of 
the starting isatin. The organic (DCM) phase was washed twice with saturated aqueous 
solution NaCl, dried with anhydrous sodium sulfate, filtered and evaporated. After 
purification by flash chromatography using ethyl AcOEt/n-hexane as eluent. Compound 
was washed with ether in order to get the final product. 
 
4.2.3.1 Synthesis of 5-chloro-3',5'-diphenyl-3'H-spiro[indoline-3,2'-
[1,3,4]oxadiazol]-2-one (32a) 
 
Following the general procedure, 253.9 mg of 29a (1.101 mmol, 2 eq) was 
added to 100,4 mg of 5-Cl isatine (0.551 mmol, 1eq.) which was dissolved in DCM (3 
mL). Then, 153 mL of TEA (1.101 mmol, 2 eq.) was added added in a dropwise 
manner. Synthesized according to the general procedure, compound 32a was obtained 






MP 200 – 202 ºC; IR υmax (KBr, selected peaks): 3251 
(NH), 1734 (C=O), 1599 (C=N), 1495, 1474, 1375, 1205, 




H NMR (300 MHz, Acetone-d6) δ 
10.09 (br-s, 1H, NH), 7.91 – 7.86 (m, 2H, H-A2,6), 7.63 (d, J 
= 2.2 Hz, 1H, H-4), 7.56 – 7.50 (m, 4H, H-6, H-A3,4,5), 7.22 
– 7.15 (m, 3H, H-B3,5, H-7), 6.93 – 6.88 (m, 2H, H-B2,6), 
6.88 – 6.81 (m, 1H, H-B4) ppm.; 
13
C NMR δ (75 MHz, Acetone-d6) δ 171.61 (C=O), 
152.76 (C=N), 143.19 (ArCq-B), 142.40 (ArCq-7a), 133.47 (ArC), 131.73 (ArC), 
130.05 (ArC), 129.71 (ArC), 129.08 (ArCq-A), 127.15 (ArC), 127.05 (ArC), 126.60 
(Cq-3a), 125.73 (ArC), 121.86 (ArC), 114.86 (ArC), 113.89 (ArC), 95.72 (Cspiro) ppm. 




4.2.4 Synthesis of 7-bromo-3',5'-diphenyl-3'H-spiro[indoline-3,2'-
[1,3,4]oxadiazol]-2-one (32b) 
Following the general procedure, 153.10 mg of 29a (0.66 mmol, 2 eq) was added 
to 74.9 mg of 7-Br isatine (0.332 mmol, 1eq.) which was dissolved in DCM (3 mL). 
Closed round bottom flask and put the Nitrogen gas balloon. Then, 0.09 mL of TEA 
(0.66 mmol, 2 eq.) was added. Synthesized according to the general procedure, 
compound 32b was obtained as a dark yellow solid in a 46% yield. Reaction time: 16h. 
MP 235 - 237ºC; IR υmax (KBr, selected peaks): 3421 (NH), 





H NMR (300 MHz, Acetone-d6) δ 10.23 (br-s, 
1H, NH), 7.94 – 7.83 (m, 2H, H-A2,6), 7.69 (d, J = 8.2 Hz, 1H, 
H-4), 7.58 – 7.46 (m, 4H, H-6, H-A3,4,5), 7.24 – 7,15 (m, 2H, H-
B3,5), 7.15 – 7.07 (m, 1H, H-5), 6.93 – 6,81 (m, 3H H-B2,4,6) 
ppm.; 
13
C NMR δ (75 MHz, Acetone-d6) δ 171.67 (C=O), 152.80 (C=N), 143.18 
(ArCq-B), 142.91 (ArCq-7a), 136.34 (ArC), 131.77 (ArC), 130.05 (ArC), 129.71 (ArC), 
130.07 (ArCq-A), 129.74 (ArC), 127.02 (ArC), 126.61 (Cq-3a), 126.06 (ArC), 125.92 
(ArC), 125.65 (ArC), 121.91 (ArC), 114.92 (ArC), 104.86 (ArC), 96.50 (Cspiro) ppm. 






4.2.5 Synthesis of 6-chloro-3',5'-diphenyl-3'H-spiro[indoline-3,2'-
[1,3,4]oxadiazol]-2-one (32c) 
Following the general procedure, 190.6 mg of 29a (0.826 mmol, 2 eq) was added 
to 78.8 mg of 6-Cl isatine (0.413 mmol, 1eq.) which was dissolved in DCM (3 mL). 
Closed round bottom flask and put the Nitrogen gas balloon. Then, 0.112 mL of TEA 
(0.826 mmol, 2 eq.) was added. Synthesized according to the general procedure, 
compound 32c was obtained as a light yellow solid in a 54% yield. Reaction time: 18h. 
MP 239 – 241ºC; IR υmax (KBr, selected peaks): 3179 (NH), 
1737 (C=O), 1598 (C=N), 1493, 1452, 1366, 1287, 1130, 




H NMR (300 MHz, Acetone-d6) 
δ 10.10 (br-s, 1H, NH), 7.88 (ddd, J = 3.7, 3.1, 1.5 Hz, 2H, 
H-A2,6), 7.57 – 7.50 (m, 4H, H-5, H-A3,4,5), 7.21 – 7.14 (m, 
4H, H-B3,5, H-4, H-7), 6.93 – 6.88 (m, 2H, H-B2,6), 6.88 – 
6.80 (m, 1H, H-B4) ppm.; 
13
C NMR δ (75 MHz, Acetone-d6) δ 171.84 (C=O), 152.77 
(C=N), 145.02 (ArCq-B), 143.28 (ArCq-7a), 138.61 (ArC), 131.72 (ArC), 130.02 
(ArC), 129.72 (ArC), 128.45 (ArCq-A), 127.00 (ArC), 125.74 (ArC), 124.26 (Cq-3a), 
123.44 (ArC), 121.85 (ArC), 114.94 (ArC), 112.79 (ArC), 95.56 (Cspiro) ppm. 




4.2.6 Synthesis of 7-chloro-3',5'-diphenyl-3'H-spiro[indoline-3,2'-
[1,3,4]oxadiazol]-2-one (32d) 
Following the general procedure, 190.6 mg of 29a (0.826 mmol, 2 eq) was added 
to 75.5 mg of 7-Cl isatine (0.413 mmol, 1eq.) which was dissolved in DCM (3 mL). 
Closed round bottom flask and put the Nitrogen gas balloon. Then, 0.112 mL of TEA 
(0.826 mmol, 2 eq.) was added. For this compound column was repeated with flash 
chromatography. Synthesized according to the general procedure, compound 32d was 






MP 240 - 242ºC; 
1
H NMR (300 MHz, Acetone-d6) δ 10.32 (br-
s, 1H, NH), 7.94 – 7.83 (m, 2H, H-A2,6), 7.60 – 7.47 (m, 5H, H-
5, H-6, H-A3,4,5), 7.23 – 7.14 (m, 3H, H-B3,5, H-4), 6.94 – 6.87 
(m, 2H, H-B2,6), 6.84 (d, J = 7.4 Hz, 1H, H-B4) ppm; 






4.2.7 Synthesis of 3',5'-diphenyl-3'H-spiro[indoline-3,2'-
[1,3,4]oxadiazol]-2-one (32e) 
Following the general procedure, 235.19 mg of 29a (0.826 mmol, 2 eq) was 
added to 75.8 mg of isatine (0.51 mmol, 1eq.) which was dissolved in DCM (3 mL). 
Closed round bottom flask and put the Nitrogen gas balloon. Then, 0.138 mL of TEA 
(0.826 mmol, 2 eq.) was added. For this compound column was repeated with flash 
chromatography. Synthesized according to the general procedure, compound 32e was 
obtained as a light yellow solid in a 90% yield. Reaction time: 16h. 
 
MP 235-237ºC; IR υmax (KBr, selected peaks): 3151 (NH), 





H NMR (300 MHz, Acetone-d6) δ 9.95 (br s, 1H, 
NH), 7.93 – 7.86 (m, 2H, H-A2,6), 7.57 – 7.45 (m, 5H, H-A3,4,5, 
H-5, H-6), 7.21 – 7.09 (m, 4H, H-B3,5, H-4, H-7), 6.94 – 6.88 
(m, 2H, H-B2,6), 6.83 (ddd, J = 8.4, 2.2, 1.1 Hz, 1H, H-B4) 
ppm;  13C NMR δ (75 MHz, Acetone-d6) δ 171.88 (C=O), 152.76 (C=N), 143.63 
(ArCq-B), 143.41 (ArCq-7a), 133.56 (ArC), 131.63 (ArC), 129.92 (ArC), 129.70 (ArC), 
127.00 (ArCq-A), 126.97 (ArC), 125.91 (ArC), 125.77 (ArC), 124.33 (Cq-3a), 124.33 
(ArC), 121.55 (ArC), 114.76 (ArC), 112.26 (ArC), 96.04 (Cspiro) ppm.
 






4.2.8 Synthesis of 5-bromo-3',5-diphenyl-3'H-spiro[indoline-3,2'-
[1,3,4]oxadiazol]-2-one (32f) 
Following the general procedure, 153.2 mg of 29a (0.826 mmol, 2 eq) was added 
to 74.9 mg of 5-Br isatine (0.332 mmol, 1eq.) which was dissolved in DCM (3 mL). 
Closed round bottom flask and put the Nitrogen gas balloon. Then, 0.09 mL of TEA 
(0.664 mmol, 2 eq.) was added. For this compound column was repeated with flash 
chromatography. Synthesized according to the general procedure, compound 32f was 
obtained as a dark yellow solid in a 57% yield. Reaction time: 17h.  
 
MP 236 - 238ºC;
 1
H NMR (300 MHz, Acetone-d6) δ 10.08 
(br s, 1H, NH), 7.92 – 7.86 (m, 2H, H-A2,6), 7.75 (d, J = 2.1 
Hz, 1H, H-4), 7.67 (dd, J = 8.3, 2.1 Hz, 1H, H-6), 7.56 – 
7.48 (m, 3H, H-A3,4,5), 7.23 – 7.15 (m, 2H, H-B3,5), 7.13 (d, 
J = 8.3 Hz, 1H, H-7), 6.94 – 6.88 (m, 2H, H-B2,6), 6.88 – 
6.82 (m, 1H, H-B4) ppm; 
13
C NMR δ (75 MHz, Acetone-d6) 
δ 171.48 (C=O), 152.75 (C=N), 143.17 (ArCq-B), 142.83 (ArCq-7a), 139.37 (ArC), 
131.72 (ArC), 130.05 (ArC), 129.94 (ArC), 129.70 (ArCq-A), 127.04 (ArC), 126.94 
(Cq-3a), 125.72 (ArC), 121.85 (ArC), 114.83 (ArC), 114.31 (ArC), 95.72 (Cspiro) ppm.
 




4.2.9 Synthesis of 6-chloro-5'-(4-methoxyphenyl)-3'-phenyl-3'H-
spiro[indoline-3,2'-[1,3,4]oxadiazol]-2-one (32g) 
Following the general procedure, 215.38 mg of 29c (0.826 mmol, 2 eq) was 
added to 74.9 mg of 6-Cl isatine (0.332 mmol, 1eq.) which was dissolved in DCM (3 
mL). Closed round bottom flask and put the Nitrogen gas balloon. Then, 0.112 mL of 
TEA (0.826 mmol, 2 eq.) was added. Synthesized according to the general procedure, 






MP 159 - 162ºC;
1
H NMR (300 MHz, Acetone-d6) δ 
10.10 (br-s, 1H, NH), 7.88 (ddd, J = 3.7, 3.1, 1.5 Hz, 
2H, H-A2,6), 7.57 – 7.50 (m, 4H, H-5, H-A3,4,5), 7.21 – 
7.14 (m, 4H, H-B3,5, H-4, H-7), 6.93 – 6.88 (m, 2H, H-
B2,6), 6.88 – 6.80 (m, 1H, H-B4) ppm.; 




4.2.10 4.2.3 Synthesis of 6-chloro-3',5'-diphenyl-3'H-spiro[indoline-
3,2'-[1,3,4]oxadiazol]-2-one(32h) 
Following the general procedure, a solution of a 3-chloro-N'-(3-chlorophenyl) 
benzohydrazonyl chloride (247,49 mg) in DCM (3 ml) was added to 6-chloro isatine 
(75,0 mg) and TEA (112,06µL) was added in a dropwise manner. Synthesized 
according to the general procedure, compound 32h was obtained as a light yellow solid 
in a 65% yield. Reaction time: 22h. 
 
MP 232 - 234ºC; 
1
H NMR (300 MHz, Acetone-d6) δ 
10.08 (br s, 1H, NH), 7.92 – 7.86 (m, 2H, H-A2,6), 7.75 
(d, J = 2.1 Hz, 1H, H-4), 7.67 (dd, J = 8.3, 2.1 Hz, 1H, 
H-6), 7.56 – 7.48 (m, 3H, H-A3,4,5), 7.23 – 7.15 (m, 2H, 
H-B3,5), 7.13 (d, J = 8.3 Hz, 1H, H-7), 6.94 – 6.88 (m, 




4.2.11 Synthesis of 5-bromo-5'-(3-chlorophenyl),3'-(3-chlorophenyl)-
3'H-spiro[indoline-3,2'-[1,3,4]oxadiazol]-2-one(32i) 
Following the general procedure, a solution of a 3-chloro-N'-(3-chlorophenyl) 
benzohydrazonoyl chloride (198,81 mg) in DCM (3 ml) was added to 5-bromo isatine 




to the general procedure, compound 32h was obtained as a light yellow solid in a 58% 
yield. Reaction time: 19h.  
 
MP 235-236ºC; IR υmax (KBr, selected peaks): 3418 




H NMR (300 MHz, Acetone-d6) δ 10.08 (br s, 1H, 
NH), 7.92 – 7.86 (m, 2H, H-A2,6), 7.75 (d, J = 2.1 Hz, 
1H, H-4), 7.67 (dd, J = 8.3, 2.1 Hz, 1H, H-6), 7.56 – 
7.48 (m, 3H, H-A3,4,5), 7.23 – 7.15 (m, 2H, H-B3,5), 
7.13 (d, J = 8.3 Hz, 1H, H-7), 6.94 – 6.88 (m, 2H, H-
B2,6), 6.88 – 6.82 (m, 1H, H-B4) ppm; 
13
C NMR δ (75 MHz, Acetone-d6) δ 170.83 
(C=O), 152.25 (C=N), 143.96 (ArCq-B), 142.84 (ArCq-7a), 136.82 (ArC), 135.54 
(ArC), 135.25 (ArC), 131.84 (ArC), 131.64 (ArC), 130.19 (ArCq-A), 127.32 (ArC), 
126.81 (ArC), 126.00 (Cq-3a), 125.64 (ArC), 121.72 (ArC), 116.46 (ArC), 114.92 
(ArC), 114.51 (ArC), 112.57 (ArC), 95.70 (Cspiro) ppm. 




4.2.12 Synthesis of 5-chloro-5'-(3-chlorophenyl),3'-(3-chlorophenyl)-
3'H-spiro[indoline-3,2'-[1,3,4]oxadiazol]-2-one(32j) 
Following the general procedure, a solution of a 3-chloro-N'-(3-chlorophenyl) 
benzohydrazonoyl chloride (247,49 mg) in DCM (3 ml) was added to 5-chloro isatine 
(75,0 mg) and TEA (112,06 µL) was added in a dropwise manner. Synthesized 
according to the general procedure, compound 32j was obtained as a light yellow solid 
in a 75% yield. Reaction time: 19h. 
 
MP 234-235ºC; IR υmax (KBr, selected peaks): 3418 





H NMR (300 MHz, Acetone-d6) δ 10.08 (br s, 1H, 
NH), 7.92 – 7.86 (m, 2H, H-A2,6), 7.75 (d, J = 2.1 Hz, 
1H, H-4), 7.67 (dd, J = 8.3, 2.1 Hz, 1H, H-6), 7.56 – 




7.13 (d, J = 8.3 Hz, 1H, H-7), 6.94 – 6.88 (m, 2H, H-B2,6), 6.88 – 6.82 (m, 1H, H-B4) 
ppm; 
13
C NMR δ (75 MHz, Acetone-d6) δ 170.83 (C=O), 152.25 (C=N), 143.98 (ArCq-
B), 142.38 (ArCq-7a), 135.53 (ArC), 135.25 (ArC), 133.91 (ArC), 131.84 (ArC), 
131.63 (ArC), 129.35 (ArCq-A), 127.40 (ArC), 127.31 (ArC), 126.81 (Cq-3a), 127.31 
(ArC), 125.64 (ArC), 121.72 (ArC), 114.93 (ArC), 114.09 (ArC), 112.60 (ArC), 95.77 
(Cspiro) ppm. 




4.2.13 Synthesis of 5-chloro-5'-(4-chlorophenyl)-3'-phenyl-3'H-
spiro[indoline-3,2'-[1,3,4]oxadiazol]-2-one(32k) 
Following the general procedure, a solution of a N'-(4-
chlorophenyl)benzohydrazonoyl chloride (219,03 mg) in DCM (4,13 ml) was added to 
5-chloro isatine (75,0 mg) and TEA (112,06 µL) was added in a dropwise manner. 
Synthesized according to the general procedure, compound 32k was obtained as a light 
yellow solid in a 69% yield. Reaction time: 16h. 
 
MP 237-239ºC; IR υmax (KBr, selected peaks): 3369 
(NH), 1763 (C=O), 1593 (C=N), 1493, 1474, 1395, 




H NMR (300 MHz, 
Acetone-d6) δ 10.08 (br s, 1H, NH), 7.92 – 7.86 (m, 
2H, H-A2,6), 7.75 (d, J = 2.1 Hz, 1H, H-4), 7.67 (dd, J 
= 8.3, 2.1 Hz, 1H, H-6), 7.56 – 7.48 (m, 3H, H-A3,4,5), 
7.23 – 7.15 (m, 2H, H-B3,5), 7.13 (d, J = 8.3 Hz, 1H, H-
7), 6.94 – 6.88 (m, 2H, H-B2,6), 6.88 – 6.82 (m, 1H, H-B4) ppm; 
13
C NMR δ (75 MHz, 
Acetone-d6) δ 171.29 (C=O), 153.24 (C=N), 142.39 (ArCq-B), 142.06 (ArCq-7a), 
133.66 (ArC), 131.94 (ArC), 129.74 (ArC), 129.49 (ArC), 129.39 (ArC), 129.21 (ArCq-
A), 128.19 (ArC), 127.23 (ArC), 127.16 (Cq-3a), 126.26 (ArC), 126.10 (ArC), 125.48 
(ArC), 116.35 (ArC), 114.04 (ArC), 95.70 (Cspiro) ppm. 
ESI-MS m/z: 409.04 [M+H]
+
. Anal. Calcd. (C21H13Cl2N3O2): C, 61.48%; H, 3.19%; N, 







4.2.14 Synthesis of 5-bromo-5'-(4-chlorophenyl)-3'-phenyl-3'H-
spiro[indoline-3,2'-[1,3,4]oxadiazol]-2-one(32l) 
Following the general procedure, a solution of a N'-(4-
chlorophenyl)benzohydrazonoyl chloride (175,96 mg) in DCM (3,31 ml) was added to 
5-bromo isatine (75,0 mg) and TEA (90,02 µL) was added in a dropwise manner. 
Synthesized according to the general procedure, compound 32l was obtained as a light 
yellow solid with 66% yield. Reaction time: 16h. 
 
MP 243 - 245ºC; 
1
H NMR (300 MHz, Acetone-d6) δ 
10.08 (br s, 1H, NH), 7.92 – 7.86 (m, 2H, H-A2,6), 7.75 
(d, J = 2.1 Hz, 1H, H-4), 7.67 (dd, J = 8.3, 2.1 Hz, 1H, 
H-6), 7.56 – 7.48 (m, 3H, H-A3,4,5), 7.23 – 7.15 (m, 2H, 
H-B3,5), 7.13 (d, J = 8.3 Hz, 1H, H-7), 6.94 – 6.88 (m, 
2H, H-B2,6), 6.88 – 6.82 (m, 1H, H-B4) ppm; 
13
C NMR 
δ (75 MHz, Acetone-d6) δ 171.36 (C=O), 155.14 
(C=N), 149.62 (ArCq-B), 141.20 (ArCq-7a), 134.01 (ArC), 132.64 (ArC), 129.48 
(ArC), 129.39 (ArC), 128.20 (ArCq-A), 127.93 (Cq-3a), 124.50 (ArC), 120.55 (ArC), 
115.76 (ArC), 115.36 (ArC), 115.22 (ArC), 95.70 (Cspiro) ppm. 
ESI-MS m/z: 456.1 [M+H]
+
. Anal. Calcd. (C21H13BrClN3O2): C, 55.47%; H, 2.88%; N, 





4.3 Biological Experiments 
HCT116 cells were grown in McCoy’s 5A supplemented with 10% fetal bovine 
serum (FBS) (Invitrogen, Grand Island, NY, USA), 1% GlutaMAXTM (Invitrogen) and 
1% penicillin/streptomycin solution (Sigma-Aldrich, St Louis, MO, USA). SW620 cells 
were grown in DMEM (Invitrogen) supplemented with 10% FBS and 1% 
antibiotic/antimycotic solution (Sigma-Aldrich). For cell viability assays cells were 
seeded at 1 x 10
5
 cells/mL (HCT116 and SW620); (HCT116, SW620) and for flow 
cytometry analysis cells were seeded at 3 × 10
5
 cells/mL. HCT116 human colorectal 
carcinoma cells rendered p53-null by somatic knockout were a kind gift from Dr. Bert 
Vogelstein (Johns Hopkins University, Baltimore, MD). 
 
In vitro cytotoxicity assay 
The cellular growth inhibitory activity was evaluated in four cell lines: an 





], human colorectal adenocarcinoma cell lines [SW620 
(mut p53)] and normal colon fibroblasts (CCD-18Co). 
 
HCT116, SW620 cells were incubated with vehicle or the compounds 
approximately 24 h after plating. For the assays with these cell lines, the compounds 
were dissolved in DMSO and diluted in culture medium to a range of concentrations 
from 0.5 to 200 μM (at least twelve concentrations were used). CCD-18Co cells were 
grown in DMEM supplemented with 10% FBS; 1% Pen/Strep; 1% Glutamate; 1% Non-
essential amino acids (NEAA); 0.025% TNF-alpha Human. The final concentration of 
DMSO in culture medium during treatment did not exceed 0.8% (v/v) and the same 
concentration of DMSO was added to the control. Each compound concentration and 
DMSO was tested in duplicate in a single experiment that was repeated 3 times. Cells 
were incubated at 37 ºC in humidified 5% CO2 atmosphere. Cell viability was assessed 
72 h after compound incubation by using the CellTiter96® AQueous Non-Radioactive 
Cell Proliferation Assay (Promega), according to the manufacturer’s protocol. The 
method is based on the reduction of MTS tetrazolium compound by viable cells to 




absorbance was measured at 490 nm using Bio-Rad microplate reader Model 680 (Bio-
Rad, Hercules, CA, USA). 
The concentrations of the compounds that inhibited cell growth by 50% (IC50) 
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